Ophthalmology – Leber Hereditary Optic Neuropathy

Basics

Description

Leber hereditary optic neuropathy (LHON) is a mitochondrial optic neuropathy that causes acute or subacute, painless central visual loss, usually beginning in one eye and then affecting the fellow eye within weeks to months.

The disease is caused by maternally inherited mitochondrial DNA mutations that impair oxidative phosphorylation.

Typical features include:

• Painless central visual loss
• Central or cecocentral scotoma
• Dyschromatopsia
• Sequential involvement of the fellow eye
• Predominance in young adult males

Visual acuity often deteriorates to 20/200 or worse.

Epidemiology

LHON is uncommon.

Reported incidence in European populations is approximately 1 in 30,000 to 1 in 50,000.

The disease most commonly becomes symptomatic between 18 and 35 years of age, although onset can occur in childhood or later adulthood.

Men are affected much more frequently than women.

Risk Factors

The most important risk factor is inheritance of a pathogenic mitochondrial DNA mutation from the mother.

Environmental factors may influence whether a carrier develops visual loss.

Important modifiable risk factors include:

• Smoking
• Heavy alcohol consumption
• Exposure to mitochondrial toxins
• Certain medications with mitochondrial toxicity
• Nutritional deficiency in susceptible individuals

Smoking appears to be particularly important in genetically susceptible carriers.

Genetics

LHON is inherited through mitochondrial DNA, so transmission is maternal.

Affected men do not transmit the mutation to their children.

Affected or carrier women may transmit the mutation to all of their children.

The three major pathogenic mutations are:

• m.3460G>A
• m.11778G>A
• m.14484T>C

Together, these account for the great majority of LHON cases.

The m.11778G>A mutation is the most common.

Penetrance

Not every individual carrying an LHON mutation develops optic neuropathy.

Penetrance is incomplete and strongly influenced by sex.

Men have a substantially greater lifetime risk of visual loss than women.

This means that a family can contain:

• Asymptomatic carriers
• Severely affected individuals
• Individuals with onset at different ages

despite carrying the same mitochondrial mutation.

Heteroplasmy

Some patients have heteroplasmy, meaning both normal and mutant mitochondrial DNA coexist in the same individual.

Others are homoplasmic, meaning essentially all mitochondrial DNA carries the mutation.

The proportion of mutant mitochondrial DNA may influence disease risk, although blood heteroplasmy does not necessarily reflect the exact mitochondrial composition within the optic nerve.

Pathophysiology

The major LHON mutations affect subunits of mitochondrial complex I, also called NADH dehydrogenase.

This impairs oxidative phosphorylation and reduces efficient cellular energy production.

Retinal ganglion cells, particularly those forming the papillomacular bundle, have high metabolic demands and appear especially susceptible.

The result is:

• Retinal ganglion cell dysfunction
• Axonal degeneration
• Optic nerve atrophy
• Permanent central visual loss in many patients

Oxidative stress and free-radical injury also appear to contribute.

General Prevention

In known carriers or affected families, patients should be advised to avoid:

• Smoking
• Heavy alcohol use
• Recreational toxins
• Unnecessary exposure to mitochondrial-toxic medications

A healthy balanced diet is reasonable.

These measures do not guarantee prevention but may reduce environmental stress on vulnerable mitochondria.

Commonly Associated Conditions

Most patients have isolated optic neuropathy.

Rare systemic manifestations can occur, including:

• Cardiac conduction abnormalities
• Wolff-Parkinson-White syndrome
• Other pre-excitation syndromes
• Prolonged QT interval
• Palpitations
• Syncope

Rare neurologic manifestations include:

• Tremor
• Ataxia
• Dystonia
• Hyperreflexia
• Peripheral neuropathy
• Hearing impairment
• Movement disorders
• Nystagmus

A multiple sclerosis-like syndrome associated with LHON is sometimes referred to as LHON-plus.

Diagnosis

History

The classic presentation is:

• Painless visual decline
• Initially involving one eye
• Followed by the fellow eye weeks or months later

Approximately half of patients develop fellow-eye involvement within a few months.

Patients may describe:

• Central blur
• Loss of fine detail
• Difficulty recognizing faces
• Reduced color perception
• Central blind spot

Peripheral vision is often relatively preserved.

Visual Acuity

Visual acuity may initially be mildly reduced but often declines substantially.

Many affected eyes reach:

• 20/200
• Counting fingers
• Occasionally worse

The degree of visual loss varies.

Color Vision

Color vision impairment can occur before major loss of central acuity.

Patients may have:

• Red-green dyschromatopsia
• Generalized color desaturation
• Difficulty with formal color plate testing

Color testing is useful in monitoring optic nerve dysfunction.

Visual Fields

The characteristic defect is a:

• Central scotoma
• Cecocentral scotoma

The defect often enlarges as the disease progresses.

Peripheral visual fields are usually better preserved than central vision.

Fundus Findings

During the acute phase, classic findings may include:

• Circumpapillary telangiectatic microangiopathy
• Peripapillary retinal nerve fiber layer swelling
• Vascular tortuosity
• Hyperemia of the optic disc

Importantly, there is typically little or no leakage from the optic disc on fluorescein angiography, despite the appearance of swelling.

This helps distinguish LHON from true inflammatory optic disc edema.

Pseudoedema

The peripapillary nerve fiber layer may appear swollen, but this is not typical inflammatory disc edema.

Fluorescein angiography generally shows absence of significant disc leakage.

Over time, swelling resolves and is replaced by:

• Temporal pallor
• Diffuse optic atrophy
• Thinning of the retinal nerve fiber layer

Diagnostic Tests

Genetic Testing

Mitochondrial DNA testing is the most important confirmatory test.

Testing should initially include the three major mutations:

• m.3460G>A
• m.11778G>A
• m.14484T>C

Broader mitochondrial sequencing may be considered when clinical suspicion is high but these common mutations are absent.

Optical Coherence Tomography

OCT is useful for documenting structural changes.

Early disease may show:

• Thickening of the retinal nerve fiber layer
• Peripapillary swelling

Later disease shows:

• RNFL thinning
• Ganglion cell complex loss
• Optic atrophy

Ganglion cell loss may become detectable early in the disease course.

Fluorescein Angiography

Fluorescein angiography may demonstrate:

• Peripapillary telangiectatic vessels
• Microangiopathy

A characteristic feature is the absence of significant leakage from the disc.

Visual Evoked Potentials

VEPs may show:

• Reduced amplitude
• Delayed latency
• Absent responses in severe disease

They are supportive but not diagnostic.

Color Testing

More detailed testing may include:

• Farnsworth D-15
• Farnsworth-Munsell 100 Hue test

These can detect optic nerve dysfunction before severe central vision loss.

Cardiac Evaluation

An ECG may be considered because some LHON patients have associated cardiac conduction abnormalities.

This is particularly appropriate if the patient reports:

• Palpitations
• Syncope
• Exercise intolerance

Neuroimaging

MRI of the brain and orbits may be obtained, particularly in atypical cases or when excluding other optic neuropathies.

MRI is often normal or nonspecific.

Imaging is important when the presentation is unusual because LHON can mimic:

• Optic neuritis
• Compressive optic neuropathy
• Demyelinating disease

Differential Diagnosis

Important differential diagnoses include:

• Dominant optic atrophy
• Nutritional optic neuropathy
• Toxic optic neuropathy
• Tobacco-alcohol optic neuropathy
• Multiple sclerosis-associated optic neuritis
• Compressive optic neuropathy
• Wolfram syndrome
• Other inherited mitochondrial optic neuropathies

Dominant Optic Atrophy

Dominant optic atrophy usually presents:

• Earlier in life
• More gradually
• Bilaterally and symmetrically

LHON more typically causes relatively rapid sequential central visual loss.

Optic Neuritis

Typical demyelinating optic neuritis often causes:

• Eye pain with movement
• More acute unilateral loss
• Younger adult presentation
• MRI abnormalities in many cases

LHON is characteristically painless and frequently becomes bilateral sequentially.

Toxic and Nutritional Optic Neuropathy

These may also produce:

• Bilateral central scotomas
• Dyschromatopsia
• Temporal optic pallor

A careful history of:

• Alcohol
• Tobacco
• Medications
• Nutritional status

is essential.

Treatment

Idebenone

Modern management may include idebenone, a synthetic short-chain benzoquinone related to coenzyme Q10.

It is intended to improve mitochondrial electron transport and reduce oxidative stress.

Benefit appears greatest when treatment is started relatively early in the disease course.

Availability and approval vary by country, and management should be coordinated with a neuro-ophthalmologist or mitochondrial disease specialist.

Supportive Metabolic Therapy

Historically, various supplements have been used, including:

• Coenzyme Q10
• Riboflavin
• Thiamine
• Vitamin B12
• Folic acid
• L-carnitine
• Alpha-lipoic acid
• Antioxidants

Evidence for many of these therapies is limited compared with idebenone.

They should not replace specialist-directed treatment.

Gene Therapy

Gene therapy has been studied extensively for LHON, particularly for the m.11778G>A mutation.

Several trials have investigated intravitreal delivery of mitochondrial-targeted genetic constructs.

This remains a rapidly evolving area and availability depends on region and regulatory approval.

Surgery

There is no useful surgical treatment for the underlying mitochondrial optic neuropathy.

Procedures such as optic nerve sheath decompression do not improve LHON.

Referral

Patients with suspected LHON should be referred to a:

• Neuro-ophthalmologist
• Medical geneticist or genetic counselor
• Mitochondrial disease specialist when appropriate

Cardiology referral may be indicated if conduction abnormalities are suspected.

Low-Vision Rehabilitation

Because central vision may be severely affected while peripheral vision remains relatively intact, low-vision services are extremely important.

Useful interventions may include:

• Magnifiers
• Electronic reading devices
• Screen magnification
• Text-to-speech software
• High-contrast aids
• Orientation and mobility training

Visual rehabilitation can substantially improve independence.

Genetic Counseling

Genetic counseling is essential.

Important inheritance principles include:

• Transmission is maternal.
• An affected father does not transmit LHON mtDNA to his children.
• A carrier mother can transmit the mutation to both sons and daughters.
• Not every carrier develops visual loss.
• Men are more likely to become affected than women.

Female relatives are especially important to identify because they can transmit the mutation to future generations.

Follow-Up

Patients should be monitored with:

• Visual acuity
• Color vision
• Visual fields
• OCT
• Fundus examination

During the acute phase, relatively frequent follow-up may help document progression from one eye to the other and monitor structural changes.

Patient Education

Patients should be advised to:

• Stop smoking
• Avoid heavy alcohol consumption
• Maintain good nutrition
• Avoid unnecessary mitochondrial-toxic exposures
• Inform physicians of the mitochondrial diagnosis before starting new medications
• Seek genetic counseling
• Use low-vision rehabilitation early if needed

Family members may benefit from genetic testing after appropriate counseling.

Prognosis

The prognosis varies considerably according to the mitochondrial mutation.

m.11778G>A

This mutation generally has the poorest spontaneous visual recovery.

m.14484T>C

This mutation has a significantly better chance of partial spontaneous recovery.

m.3460G>A

The prognosis is generally intermediate.

Better recovery has also been associated with:

• Younger age at onset
• Larger optic disc size in some studies
• Earlier treatment
• Certain mitochondrial genetic backgrounds

Visual Recovery

When recovery occurs, patients may notice:

• Small islands of clearer vision within the central scotoma
• Gradual improvement in central acuity
• Better color perception

Recovery can occur months or even years after onset.

However, many patients are left with significant permanent central visual impairment.

Complications

The principal complication is permanent bilateral central visual loss.

Secondary consequences may include:

• Loss of driving ability
• Difficulty reading
• Occupational limitations
• Reduced independence
• Psychosocial distress

Rare systemic complications include cardiac conduction abnormalities and neurologic manifestations.

The key clinical pearl is: LHON should be suspected in a young adult—especially a man—with painless, severe central visual loss in one eye followed weeks to months later by similar involvement of the fellow eye, particularly when maternal male relatives have experienced comparable visual loss.